Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of QX-4533 in Healthy Volunteers and of Multiple Doses of QX-4533 in Participants With Moderate-to-Severe Atopic Dermatitis

NCT07800104 is registered in ClinicalTrials.gov with QuantX Biosciences, Inc. as lead sponsor.

NCT NCT07800104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07800104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of QX-4533 in Healthy Volunteers and of Multiple Doses of QX-4533 in Participants With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
QuantX Biosciences, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 14, 2026
Completion date
May 19, 2027
Enrollment
84 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis